ReviewTherapeutic advances in neurological disorders2016
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
Review in Therapeutic advances in neurological disorders, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- Comparison of treatment efficacy and cost-effectiveness of rituximab and oral agents among patients with neuromyelitis optica spectrum disorders: a population-based cohort study.Therapeutic advances in neurological disorders · 2025Article
- Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the CIRCLES cohort.Journal of neurology · 2023Observational
- Adverse Events in NMOSD Therapy.International journal of molecular sciences · 2022Review
- Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.Neuropsychiatric disease and treatment · 2022Article
- Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devic's Disease) and Multiple Sclerosis-A Review.International journal of molecular sciences · 2021Review
- Treatment of Neuromyelitis Optica Spectrum Disorders.International journal of molecular sciences · 2021Review
- Article
- The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies.Journal of neuroinflammation · 2020Article
- A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder.Medicine · 2019Article
- Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.Journal of neurology · 2019Article
- Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.Neurology and therapy · 2018Article
- Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.Journal of neurology · 2018Article
- Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.The American journal of case reports · 2018Article
- Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Current treatment options in neurology · 2017Review
- The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.Advances in therapy · 2017Article
- Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies.Degenerative neurological and neuromuscular disease · 2017Review
- Real-World Budget Impact of Listing a Biosimilar of Rituximab.The Canadian journal of hospital pharmacyArticle
- Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica spectrum disorders (NMOSDs) is a new concept which includes classical neuromyelitis optica (NMO) and partial forms of NMO such as recurrent optic neuritis with positive aquaporin-4 antibodies (AQP4) or brainstem symptoms (intractable hiccups or vomiting). This disease is clearly distinguished from multiple sclerosis (MS) and the therapeutic approach is clearly different. Rituximab is actually considered to be one of the most efficient treatments of NMOSD, even if class I studies are clearly lacking. In the present review, we describe the state of the art about rituximab treatment in NMOSD, including adults and children, plus its efficacy and tolerance and we also underline the questions that should be addressed in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.